10-Q: SINTX Technologies Reports Increased Revenue but Continues to Face Losses in Q2 2024

SINTX Technologies saw a significant increase in revenue in the second quarter of 2024, but the company still experienced a net loss and is taking steps to improve operational efficiency.

Summary

• SINTX Technologies reported a net loss of $3.1 million for the six months ended June 30, 2024, compared to a $2.7 million loss for the same period in 2023.
• Total revenue increased by 48% to $1.5 million for the first six months of 2024, driven by a 45% increase in product revenue and a 50% increase in grant and contract revenue.
• The company's cost of revenue increased by 101% for the six months ended June 30, 2024, resulting in a gross profit increase of 33%.
• Operating expenses decreased by 11% to $7.0 million for the six months ended June 30, 2024, primarily due to reductions in research and development, and sales and marketing expenses.
• The company used $4.9 million in operating activities for the six months ended June 30, 2024, compared to $8.1 million for the same period in 2023.
• SINTX raised $6.3 million through financing activities in the first half of 2024, compared to $11.5 million in the first half of 2023.
• The company's cash and cash equivalents totaled $4.6 million as of June 30, 2024, compared to $3.3 million at the end of 2023.
• SINTX implemented a 1-for-200 reverse stock split on May 28, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• The company is ceasing efforts to make its armor plant operational, expecting to incur a $4.5 million impairment charge.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue growth is positive, the increasing net loss, the decision to cease operations at the armor plant, and the going concern warning from auditors create a negative outlook. The company is taking steps to improve, but significant challenges remain.

Positives

• Total revenue increased by 48% for the first six months of 2024, indicating strong growth in sales and contract revenue.
• Gross profit increased by 33% for the first six months of 2024, showing improved profitability.
• Operating expenses decreased by 11% for the first six months of 2024, demonstrating cost control efforts.
• Cash used in operating activities decreased by $3.1 million for the first six months of 2024, indicating improved cash management.
• The company successfully raised $6.3 million through financing activities in the first half of 2024.
• SINTX regained compliance with Nasdaq's minimum bid price requirement after the reverse stock split.

Negatives

• The company reported a net loss of $3.1 million for the first six months of 2024, indicating ongoing financial challenges.
• Cost of revenue increased by 101% for the first six months of 2024, outpacing revenue growth.
• The company is ceasing operations at its armor plant, resulting in a $4.5 million impairment charge.
• SINTX reduced its workforce by 42.5%, which may impact operations.
• The company's auditors have raised concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on its ability to increase sales and raise additional capital.
• The company's existing capital resources are not sufficient to fund the completion of the development and commercialization of all product candidates.
• The company may not be able to obtain additional financing on favorable terms or at all.
• The company's efforts to repair the damaged sintering furnace at the armor plant have been delayed.
• The company is subject to a Mandatory Panel Monitor by Nasdaq for one year, which could lead to delisting if the minimum bid price is not maintained.
• The company's financial results are subject to significant estimates, particularly regarding derivative liabilities and asset impairment.

Future Outlook

The company anticipates continuing to generate operating losses and use cash in operations, and its continuation as a going concern is dependent on its ability to increase sales and/or raise additional funds through the capital markets. The company is actively seeking opportunities to raise additional capital and is making changes to its sales strategy to focus on revenue growth.

Management Comments

• Management believes the publication of scientific and clinical data will help sales efforts.
• Management is making changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.
• Management is working with the insurance company to continue to fund the repair of the furnace at the armor plant.

Industry Context

SINTX operates in the advanced ceramics industry, which includes biomedical, technical, and antipathogenic applications. The company's focus on silicon nitride and other advanced ceramic materials positions it to compete in various markets, including medical implants, aerospace, and protective armor. The company's acquisition of TA&T and its entry into the ceramic armor market are strategic moves to diversify its revenue streams and leverage its expertise in advanced materials.

Comparison to Industry Standards

• SINTX's revenue growth of 48% in the first half of 2024 is notable, but it is important to compare this to other companies in the advanced ceramics and medical device industries.
• Companies like CeramTec and Kyocera, which are major players in the technical ceramics market, have established revenue streams and may serve as benchmarks for SINTX's long-term growth potential.
• In the medical device sector, companies like Medtronic and Stryker, which have a strong presence in spinal implants, can be compared to SINTX's biomedical applications, although SINTX is primarily an OEM supplier.
• The company's focus on silicon nitride for medical implants is unique, as most competitors use materials like titanium and PEEK. SINTX's claims of superior bone affinity and resistance to bacterial colonization need to be validated against industry standards.
• The decision to cease operations at the armor plant and the resulting impairment charge is a significant setback, and it is important to compare this to other companies in the protective armor market, such as Ceradyne and ArmorSource, to understand the competitive landscape.

Management Changes

Legal Proceedings

• The company is not aware of any pending or threatened legal proceedings that could have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• TA&T is obligated to repay certain personal loans made by the founders of TA&T to TA&T prior to SINTX's acquisition of TA&T. As of June 30, 2024, the outstanding balance was $7,000.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional equity financing.
• Employees have been impacted by the reduction in workforce, with 17 employees being terminated.
• Customers may experience changes in product availability or service due to the company's restructuring.
• Suppliers may be affected by the company's decision to cease operations at the armor plant.
• Creditors face the risk of non-payment if the company is unable to raise additional capital or improve its financial performance.

Next Steps

• The company will continue to seek opportunities to raise additional capital.
• The company will focus on core business areas that align with its long-term strategic goals.
• The company will work with the insurance company to continue to fund the repair of the furnace at the armor plant.
• The company will assess the costs associated with the reduction in workforce and the cessation of operations at the armor plant.
• The company will continue to generate scientific and clinical data to support sales efforts.

Key Dates

Keywords

SINTX Technologies, silicon nitride, advanced ceramics, biomedical, armor, revenue, net loss, operating expenses, reverse stock split, capital raise, Nasdaq, financial results, impairment charge